CDTX

Rezafungin

Prevention of Fungal Infections

Phase 3

Exp Date

TBD

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Rezafungin for the Prevention of Fungal Infections - Phase 3 

  • ClinicalTrial.gov (NCT04368559): Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT)


WHAT IS THE NEXT CATALYST EVENT?

  • Topline Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION

  • Rezafungin is a novel echinocandin antifungal and the only once-weekly drug candidate being developed for the first-line treatment and prevention of serious invasive fungal infections. Rezafungin has a unique pharmacokinetic profile with a prolonged half-life and front-loaded plasma exposure which, in contrast to all other echinocandins, allows for once-weekly IV therapy for inpatient and outpatient use.

Updated by JM 

CDTX, Cidara Therapeutics, Rezafungin, Prevention of Fungal Infections

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon